NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibitors of NF-κB activation attenuate the lymphoid and myeloid leukemogenesis by BCR-ABL1 and decrease the number of CML LSCs in the mouse model31.